Free Newsletter
NYT: A modest proposal to end the corruption debate
John Tierney at the New York Times writes that the fierce debate over the corrupting influence of corporate money in scientific research has become a fetish that is pushing some of the country's top researchers to stop accepting any support from drug companies. To rebalance the scales, he suggests that scientists simply detail all public and private donors on their Web pages and let journalists sort through them, leaving it to readers to decide if there is a conflict. Report
More stories about conflict of interests
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: